Ensituximab (NEO-102, NPC-1C) is a chimeric monoclonal IgG1 antibody targeting a variant of MUC5AC. Ensituximab shows specificity to colorectal and pancreatic cancer.
Purity:
98.0%
CAS Number:
[1092658-06-4]
* VAT and and shipping costs not included. Errors and price changes excepted